Literature DB >> 26296572

MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.

Dianke Yu1, Bridgett Green1, William H Tolleson1, Yaqiong Jin2, Nan Mei1, Yongli Guo2, Helen Deng3, Igor Pogribny1, Baitang Ning4.   

Abstract

Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of many drugs. Extensive studies have demonstrated that genetic variants and endogenous and environmental factors play important roles in the expression of CYP2C19. However, the role of microRNAs (miRNAs) in controlling CYP2C19 expression has not been investigated completely. In the present study, we performed in silico analysis to rank putative miRNA/CYP2C19 hybrids with regards to the predicted stabilities of their duplexes and then we applied a series of biochemical and molecular assays to elucidate the underlying functional mechanisms for the regulation of CYP2C19 by miRNAs. In silico analysis indicated that hsa-miR-23a-3p and hsa-miR-29a-3p target the coding region of CYP2C19 with hybrid stabilities of -27.5kcal/mol and -23.3kcal/mol, respectively. RNA electrophoresis mobility shift assays showed that both hsa-miR-23a-3p and hsa-miR-29a-3p miRNAs were able to bind directly to their cognate targets in the CYP2C19 transcript. Further, a significant inverse correlation was found between chemically-induced up-regulation of hsa-miR-29a-3p and CYP2C19 expression in HepaRG cells. In addition, inverse correlations were also observed in human liver tissue samples between the level of CYP2C19 mRNA expression and both hsa-miR-23a-3p and hsa-miR-29a-3p levels. All these results demonstrated the suppressing role of hsa-miR-29a-3p on CYP2C19 expression. Published by Elsevier Inc.

Entities:  

Keywords:  CYP2C19; Drug metabolizing enzymes; Inter-individual variability; Pharmacogenomics; hsa-miR-29a-3p; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26296572      PMCID: PMC5673105          DOI: 10.1016/j.bcp.2015.08.094

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  38 in total

1.  Essential and overlapping functions for mammalian Argonautes in microRNA silencing.

Authors:  Hong Su; Melanie I Trombly; Jian Chen; Xiaozhong Wang
Journal:  Genes Dev       Date:  2009-01-27       Impact factor: 11.361

2.  The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Authors:  H J Feng; S L Huang; W Wang; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

3.  Human CYP2E1 is regulated by miR-378.

Authors:  Takuya Mohri; Miki Nakajima; Tatsuki Fukami; Masataka Takamiya; Yasuhiro Aoki; Tsuyoshi Yokoi
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

4.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

Review 5.  Toxicogenomics and cancer susceptibility: advances with next-generation sequencing.

Authors:  Baitang Ning; Zhenqiang Su; Nan Mei; Huixiao Hong; Helen Deng; Leming Shi; James C Fuscoe; William H Tolleson
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2014       Impact factor: 3.781

6.  Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport.

Authors:  Xiao-bo Zhong; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2013-08-09       Impact factor: 3.922

7.  MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.

Authors:  Pooja Mandke; Nicholas Wyatt; Jillian Fraser; Benjamin Bates; Steven J Berberich; Michael P Markey
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

8.  Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.

Authors:  Dianke Yu; Bridgett Green; April Marrone; Yongli Guo; Susan Kadlubar; Dongxin Lin; James Fuscoe; Igor Pogribny; Baitang Ning
Journal:  Sci Rep       Date:  2015-02-23       Impact factor: 4.379

9.  Gene expression variability in human hepatic drug metabolizing enzymes and transporters.

Authors:  Lun Yang; Elvin T Price; Ching-Wei Chang; Yan Li; Ying Huang; Li-Wu Guo; Yongli Guo; Jim Kaput; Leming Shi; Baitang Ning
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

10.  Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma.

Authors:  Andrey Turchinovich; Barbara Burwinkel
Journal:  RNA Biol       Date:  2012-08-01       Impact factor: 4.652

View more
  24 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  FREMSA: A Method That Provides Direct Evidence of the Interaction between microRNA and mRNA.

Authors:  Dianke Yu; Si Chen; Dongying Li; Bridgett Knox; Lei Guo; Baitang Ning
Journal:  Methods Mol Biol       Date:  2020

Review 3.  Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism.

Authors:  Tomas Smutny; Lucie Hyrsova; Albert Braeuning; Magnus Ingelman-Sundberg; Petr Pavek
Journal:  Arch Toxicol       Date:  2020-11-09       Impact factor: 5.153

4.  MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.

Authors:  Dongying Li; Bridgett Knox; Si Chen; Leihong Wu; William H Tolleson; Zhichao Liu; Dianke Yu; Lei Guo; Weida Tong; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2019-08-22       Impact factor: 5.858

5.  MiR-285 targets P450 (CYP6N23) to regulate pyrethroid resistance in Culex pipiens pallens.

Authors:  Mengmeng Tian; Bingqian Liu; Hongxia Hu; Xixi Li; Qin Guo; Feifei Zou; Xianmiao Liu; Mengxue Hu; Juxin Guo; Lei Ma; Dan Zhou; Yan Sun; Bo Shen; Changliang Zhu
Journal:  Parasitol Res       Date:  2016-09-20       Impact factor: 2.289

6.  A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression.

Authors:  Bridgett Knox; Yong Wang; Lora J Rogers; Jiekun Xuan; Dianke Yu; Huaijin Guan; Jiwei Chen; Tieliu Shi; Baitang Ning; Susan A Kadlubar
Journal:  Environ Mol Mutagen       Date:  2017-12-05       Impact factor: 3.216

7.  The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.

Authors:  Yinting Chen; Linjuan Zeng; Yong Wang; William H Tolleson; Bridgett Knox; Si Chen; Zhen Ren; Lei Guo; Nan Mei; Feng Qian; Kaihong Huang; David Liu; Weida Tong; Dianke Yu; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-08-16       Impact factor: 5.858

8.  Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.

Authors:  Dianke Yu; William H Tolleson; Bridgett Knox; Yaqiong Jin; Lei Guo; Yongli Guo; Susan A Kadlubar; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2015-09-30       Impact factor: 5.858

Review 9.  Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics.

Authors:  Baitang Ning; Dianke Yu; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2019-09-10       Impact factor: 5.858

10.  A systematic evaluation of microRNAs in regulating human hepatic CYP2E1.

Authors:  Yong Wang; Dianke Yu; William H Tolleson; Li-Rong Yu; Bridgett Green; Linjuan Zeng; Yinting Chen; Si Chen; Zhen Ren; Lei Guo; Weida Tong; Huaijin Guan; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2017-04-22       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.